Cencora, Inc. (COR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Cencora highlighted strong fiscal third-quarter performance, led by growth across its core pharmaceutical distribution and specialty businesses. Management indicated Healthcare Solutions adjusted operating income growth of 14.5%-15.5%, tracking ahead of its long-term growth profile. The company expects its specialty-pharma positioning in health systems and community physician practices, supported by capital deployment, to sustain momentum into fiscal 2027 and beyond.

Analysis

COR's premium multiple depends less on distribution volume and more on sustaining specialty mix expansion without incremental working-capital drag. Specialty distribution can improve gross-profit dollars, but absolute operating-margin upside is constrained by customer concentration, manufacturer contract resets, and the financing needs of higher-cost oncology and biologic inventory. The key analytical question for the next 1-3 months is whether management quantifies specialty growth in profit dollars and cash conversion rather than relying on adjusted operating-income targets.

The competitive read-through is constructive for COR versus broadline distributors, but MCK is the cleaner paired comparator: both benefit from specialty drug inflation and provider outsourcing, while COR has greater execution sensitivity around its oncology-services strategy. A successful integrated offering could raise physician-practice customer stickiness and reduce churn; failure would leave COR with service-business overhead that does not earn distribution-like returns. Cardinal Health (CAH) is the likely relative loser if specialty scale increasingly determines manufacturer allocation and health-system contract economics.

Consensus may be underestimating reimbursement-policy risk rather than demand risk. Drug-price reform and site-of-care migration can preserve unit volumes while shifting economics away from independent practices, reducing the value of distribution-adjacent oncology services over a 6-18 month horizon. Conversely, a lower-rate backdrop would support the valuation of durable specialty earnings and reduce the carrying-cost penalty associated with inventory growth. The thesis is falsified if fiscal-2027 guidance implies decelerating Healthcare Solutions profit growth, operating cash flow trails adjusted earnings for two consecutive quarters, or specialty margin fails to expand despite continued revenue growth.

Key Decisions for Investors

• Maintain a tactical long COR / short CAH pair for the next 1-3 months, sized market-neutral. The trade expresses specialty-scale and execution differentiation while reducing healthcare-distribution beta; exit if COR's next guidance update shows Healthcare Solutions profit growth below low-teens or CAH demonstrates comparable specialty-margin acceleration.
• Do not add outright COR exposure solely on conference commentary. Establish an alert for the next earnings release: add only if management provides fiscal-2027 profit and free-cash-flow guidance consistent with specialty growth converting to cash; absent that evidence, the positive narrative is insufficient to justify multiple expansion.
• For existing COR longs, use MCK as the relative-value hedge rather than MS, which has no direct operating sensitivity. If COR materially outperforms MCK ahead of formal fiscal-2027 guidance, trim the spread because unquantified oncology-services economics create asymmetric downside on a disclosure reset.
• Monitor CMS reimbursement and site-of-care proposals over the next 6-18 months. A policy change that weakens independent oncology-practice economics is a trigger to reduce COR and consider short exposure versus MCK, unless COR demonstrates that service revenue offsets reduced practice purchasing power.